Abstract Number: PB2499
Meeting: ISTH 2020 Congress
Background: VTE is a rare but serious complication associated with HRT.
Aims: To assess the anticoagulant effect (AE) of LDW by well-known method – blood recalcification technique (BRT).
Methods: From 2016 to 2019 we studied 225 women aged 35-62 receiving HRT (estrogen). Method BRT: The recovery of ionized Ca++ initial concentration in citrated blood. In our method, we used the diminished volume of added 1,29% CaCl2 to blood than usually. We have found that this method increases the sensitivity of BRT in detection of the blood hypercoagulation (Fig.1) (patent of the RF #2015515) and helps us to see better the AE. BRT was determined by thromboelastometry (TEM) (ROTEM, Germany): time of reaction “R” – normal range = 640-960 s. Blood for first analysis was taken before HRT.
Results: The results of blood analysis demonstrated that all tested women could be divided into two groups. The 1st group of women (# 185, 82%) had normocoagulation (R=886±115 s). This group began to receive HRT immediately. We repeated the analysis after 1-1,5 months of receiving HRT. If there was normocoagulation, we continued the HRT. If we found hypercoagulation, we began treatment with warfarin (the dose was estimated individually by TEM: target range 640-960 s). The 2nd group of women (# 40, 18%) had hypercoagulation (R = 591±145 s). This group received their treatment with warfarin as preliminarily step before HRT. After getting of target range by TEM, we began HRT. There was no one case of VTE in both of groups.
Conclusions: The HRT can create the hypercoagulation and this may lead to the risk of VTE. Using the modified BRT and TEM we can not only diagnose this risk but also control the adequacy of anticoagulant treatment. LDW could be used rather effectively and at the same time with safety for elimination of hypercoagulation created by HRT.
To cite this abstract in AMA style:Sukhanov V, Vlasova N, Petrova O. Low Dose Warfarin (LDW) for the Prevention of Hypercoagulation of Blood and Venous Thromboembolism (VTE) in Women Receiving Hormone Replacement Therapy (HRT) [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/low-dose-warfarin-ldw-for-the-prevention-of-hypercoagulation-of-blood-and-venous-thromboembolism-vte-in-women-receiving-hormone-replacement-therapy-hrt/. Accessed November 29, 2023.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/low-dose-warfarin-ldw-for-the-prevention-of-hypercoagulation-of-blood-and-venous-thromboembolism-vte-in-women-receiving-hormone-replacement-therapy-hrt/